2020年4月21日 · MK-2206 is an orally active, highly potent and selective allosteric Akt inhibitor, with IC50s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell …

MK-2206 suppressed the Akt phosphorylation that is induced by carboplatin and gemcitabine. In vivo, MK-2206 in combination with these agents exerted significantly more potent tumor …

MK-2206 is an organic heterotricyclic compound that is [1,2,4]triazolo [3,4-f] [1,6]naphthyridin-3 (2H)-one substituted by 4- (1-aminocyclobutyl)phenyl and phenyl groups at positions 8 and 9, …

Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation …

2019年2月7日 · We evaluated the pan-Akt inhibitor MK-2206 in combination with standard therapy in patients with high-risk early-stage breast cancer. I-SPY 2 is a multicenter, phase II, open …

2020年2月9日 · Purpose: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic resistance in breast cancer. We evaluated the pan …

2011年10月24日 · MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in preclinical models. A phase I study of MK-2206 was conducted to investigate its …

MK-2206 is effective in reducing xenograft growth in models of breast, prostate, nonsmall cell lung, and ovarian cancers (14, 15) and has shown antitumor properties in a small phase I trial, …

2011年12月10日 · MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in preclinical models. A phase I study of MK-2206 was conducted to investigate its …